Pressmeddelande -

SenzaGen establishes subsidiary in the US

To quickly strengthen its commercial presence in the US market, Swedish SenzaGen AB expands globally and establishes a subsidiary in California.

SenzaGen, which develops and implements non-animal allergy tests of chemicals and proteins, for the chemical, pharmaceutical and cosmetic industries, expands its sales organization and prepares the company for an IPO in 2017. Senzagen, a Lund University Department of Immunotechnology spin-out was recently recognized as one of Sweden’s most promising young and innovative companies.

-In line with our strategy to establish a commercial presence in key markets, Senzagen has established a subsidiary in the US. The US represents the world's largest pharmaceutical and chemicals markets, and one of the largest within cosmetics. To capture market share, it is crucial that we have a local presence, says Anki Malmborg-Hager, CEO of SenzaGen AB.

Responsible for Senzagen’s US operations will be toxicologist Dr. Brian Rogers as US CEO, and Head of business development will be immunologist Dr. Sandra Reynoso.

-Nearly 50% of all animal research experiments today are performed in the US, and we want to be there to help replace these tests and offer the market a better and much safer test with our GARD. Together with our local team and their strong network, I look forward to building SenzaGen’s brand as the market leader in allergy testing in the US, says Anki Malmborg-Hager.

For more information, please contact:
Anki Malmborg Hager, Ph D, CEO,
E-mail: amh@senzagen.com
SE: +46 768 284822

Brian Rogers, Ph D, CEO US
brian.rogers@senzagen.com
US: +1 530 304 7648

About SenzaGen

SenzaGen provides in vitro dermal and respiratory testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company's unique test GARD is based on research from the Department of Immunotechnology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.

About GARD
By analyzing 200 and 389 genomic markers, depending on the test, instead of 1-2 markers as competing methods, GARD delivers results with 90 % accuracy. This can be compared to the golden standard, animal tests on mice, that provide 72 % accuracy. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance cause allergy.

Ämnen

  • Ekonomi, finans

Kategorier

  • chemical safety testing
  • animal free testing
  • företagsutveckling
  • business development

About SenzaGen

SenzaGen provides in vitro testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company's unique test GARD is based on research from the Department of Immune Technology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.

About GARD

By analysing 200 and 389 markers, depending on the test, instead of 1-2 markers as competing methods, GARD delivers results with 90 % accuracy. This can be compared to the golden standard, animal tests on mice, that provide only 72 % accuracy. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance cause allergy. Existing, competing tests do not achieve the same accuracy and lack the ability to measure the potency of a substance

Relaterad media

Relaterat innehåll

SenzaGen inleder samarbete med partners i Europa och USA

Det sista och viktigaste steget i SenzaGen´s formella valideringsprocess av sensibiliseringstestet GARD har nu påbörjats genom samarbeten med två externa laboratorier, Eurofins (Tyskland) och Burlesons (USA). Dessa partners kommer nu att verifiera GARD:s tillförlitlighet och reproducerbarhet, vilket innebär att testet sedan kan utföras av externa kontraktslaboratorier.

GARD godkänt för validering inom OECD

GARD, SenzaGens sensibiliteringstest, har nu inkluderats i arbetsplanen för OECD:s Test Guideline Programme (TGP) med TGP numret 4.106. Beslutet fattades vid WNT National Coordinators Tests möte i slutet av april. Valideringsprocessen för GARD kommer nu att inledas.

SenzaGen vinner DI:s Gasellsprång – mest lovande att bli Supergasell inom 5 år

På onsdagskvällen stod SenzaGen som vinnare i DI:s Gasellsprånget i den nationella finalen i Göteborg.Inledningsvis stod det mellan DigiExam och SenzaGen, men efter en tuff utfrågning och publikomröstning stod det klart att SenzaGen hade störst marknadspotential och möjlighet att ta det största språnget.

Fyll i din epostadress för att följa SenzaGen AB

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa SenzaGen AB.

Okej